Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1)
- Target
- hnRNP H1
- Molecular classification
- RNA-binding protein, Heterogeneous nuclear ribonucleoprotein (hnRNP), mRNA processing factor, Nucleic acid-binding protein
01
Overview
Heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1) is a member of a subfamily of ubiquitously expressed RNA-binding proteins that complex with heterogeneous nuclear RNA (hnRNA) during transcription and subsequent pre-mRNA processing. The protein features three quasi-RRM (RNA recognition motif) domains that mediate binding to RNA, influencing splice site choice and mRNA metabolism. hnRNP H1 functions mainly in the nucleus and is crucial for alternative splicing, mRNA export, and stability. Its dysregulation has been implicated in various diseases, including certain cancers and lymphedema. While drugs directly targeting hnRNP H1 are not in clinical use, the protein remains a notable candidate for future research into RNA-based therapeutic modulation.
- Other names
- hnRNP H1HNRNPH1Heterogeneous nuclear ribonucleoprotein HHNRPH1HNRPH
02
Mechanism of action
Unknown/unclear for direct-targeting drugs. For general modulation: alteration of RNA-protein interactions, affecting splicing, mRNA stability, or localization.
03
Biological functions
Pre-mRNA splicing (alternative splicing regulation)RNA processingRegulation of mRNA stabilitymRNA transport out of the nucleusModulation of gene expressionNuclear-cytoplasmic shuttling (some hnRNPs)Competitive splicing factor bindingScaffold for pre-mRNA processing
04
Disease associations
Cancer (notably breast cancer, cell viability/migration regulation via splicing of CD44)Hereditary lymphedema type I (potential involvement)Possibly neurodegenerative and muscle diseases (family-wide evidence, with specific splicing roles relevant in muscle and nervous tissue)Other gene expression and splicing-related pathologies
05
Safety considerations
Therapeutic targeting is challenged by ubiquity and essential roles in mRNA processing; this raises risk of widespread off-target effects, cellular toxicity, or disruption of global gene expressionFunctional redundancy within hnRNP family could complicate specific intervention.
06
Interacting drugs
Copper (reported direct interaction, but mechanism, therapeutic relevance, and specificity not established)
1 more in the full profile.
07
Biomarkers
Abnormal hnRNP H1 expression or activity may correlate with cancer progression, splicing defects, and hereditary lymphedema type INo officially validated biomarkers for clinical selection or monitoring are listed in the current literature.
Beyond the preview
Go deeper on Heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1).